1-12 of 12
Sanjay Goel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald S. Falchook, Geoffrey I. Shapiro, Ki Y. Chung, Jeffrey R. Infante, Robert M. Conry, Guilherme Rabinowits, David S. Hong, Judy S. Wang, Ulrich Steidl, Loren D. Walensky, Gurudatta Naik, Vincent Guerlavais, Vojislav Vukovic, D. Allen Annis, Manuel Aivado, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 429.
https://doi.org/10.1158/1078-0432.CCR-21-4241
Published: 15 January 2022
View article titled, Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
Open the PDF for Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 in another window
Journal Articles

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

Mansoor N. Saleh, Manish R. Patel, Todd M. Bauer, Sanjay Goel, Gerald S. Falchook, Geoffrey I. Shapiro, Ki Y. Chung, Jeffrey R. Infante, Robert M. Conry, Guilherme Rabinowits, David S. Hong, Judy S. Wang, Ulrich Steidl, Loren D. Walensky, Gurudatta Naik, Vincent Guerlavais, Vojislav Vukovic, D. Allen Annis, Manuel Aivado, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (19): 5236–5247.
https://doi.org/10.1158/1078-0432.CCR-21-0715
Published: 01 October 2021
View article titled, Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <em>TP53</em>
Open the PDF for Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <em>TP53</em> in another window
Journal Articles

Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer

Jeeshan Jiffry, Thongthai Thavornwatanayong, Devika Rao, Elisha J. Fogel, Durvanand Saytoo, Rishika Nahata, Hillary Guzik, Imran Chaudhary, Titto Augustine, Sanjay Goel, Radhashree Maitra
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (3): 865–876.
https://doi.org/10.1158/1078-0432.CCR-20-2385
Published: 01 February 2021
View article titled, Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer
Open the PDF for Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors

Filip Janku, Halle Huihong Zhang, Abdulmohammad Pezeshki, Sanjay Goel, Ravi Murthy, Andrea Wang-Gillam, Dale R. Shepard, Thorunn Helgason, Tyler Masters, David S. Hong, Sarina A. Piha-Paul, Daniel D. Karp, Mark Klang, Steven Y. Huang, Divya Sakamuri, Anjali Raina, Jean Torrisi, Stephen B. Solomon, Alice Weissfeld, Ernest Trevino, Gary DeCrescenzo, Amanda Collins, Maria Miller, Jennifer L. Salstrom, Ronald L. Korn, Linping Zhang, Saurabh Saha, Alexey A. Leontovich, David Tung, Brent Kreider, Mary Varterasian, Khashayarsha Khazaie, Mrinal M. Gounder
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (1): 96–106.
https://doi.org/10.1158/1078-0432.CCR-20-2065
Published: 04 January 2021
View article titled, Intratumoral Injection of <em>Clostridium novyi</em>-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors
Open the PDF for Intratumoral Injection of <em>Clostridium novyi</em>-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors

Bonnie S. Glisson, Rom S. Leidner, Robert L. Ferris, John Powderly, Naiyer A. Rizvi, Bhumsuk Keam, Reva Schneider, Sanjay Goel, James P. Ohr, Jennifer Burton, Yanan Zheng, Steven Eck, Matthew Gribbin, Katie Streicher, Danielle M. Townsley, Sandip Pravin Patel
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5358–5367.
https://doi.org/10.1158/1078-0432.CCR-19-3070
Published: 15 October 2020
View article titled, Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors
Open the PDF for Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma

Sant P. Chawla, Sanjay Goel, Warren Chow, Fadi Braiteh, Arun S. Singh, Juneko E. Grilley Olson, Atsushi Osada, Iulian Bobe, Richard F. Riedel
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (16): 4225–4232.
https://doi.org/10.1158/1078-0432.CCR-20-0591
Published: 14 August 2020
View article titled, A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma
Open the PDF for A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma in another window
Includes: Supplementary data
Journal Articles

Therapeutic Oligonucleotides: The Road Not Taken

Cy A. Stein, Sanjay Goel
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (20): 6369–6372.
https://doi.org/10.1158/1078-0432.CCR-11-2013
Published: 14 October 2011
View article titled, Therapeutic Oligonucleotides: The Road Not Taken
Open the PDF for Therapeutic Oligonucleotides: The Road Not Taken in another window
Includes: Supplementary data
Journal Articles

Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC

Roberto Pili, Mark A. Rosenthal, Paul N. Mainwaring, Guy Van Hazel, Sandy Srinivas, Robert Dreicer, Sanjay Goel, Joseph Leach, Shirley Wong, Peter Clingan
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (10): 2906–2914.
https://doi.org/10.1158/1078-0432.CCR-09-3026
Published: 13 May 2010
View article titled, Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC
Open the PDF for Phase II Study on the Addition of ASA404 (Vadimezan; 5,6-Dimethylxanthenone-4-Acetic Acid) to Docetaxel in CRMPC in another window
Journal Articles

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Sanjay Goel, Alain C. Mita, Monica Mita, Eric K. Rowinsky, Quincy S. Chu, Nancy Wong, Christopher Desjardins, Fang Fang, Mendel Jansen, Dale E. Shuster, Sridhar Mani, Chris H. Takimoto
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (12): 4207–4212.
https://doi.org/10.1158/1078-0432.CCR-08-2429
Published: 15 June 2009
View article titled, A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies in another window
Includes: Supplementary data
Journal Articles

A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies

Kyriakos P. Papadopoulos, Sanjay Goel, Murali Beeram, Alvin Wong, Kavita Desai, Missak Haigentz, María L. Milián, Sridhar Mani, Anthony Tolcher, Alshad S. Lalani, John Sarantopoulos
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (21): 7110–7115.
https://doi.org/10.1158/1078-0432.CCR-08-0483
Published: 03 November 2008
View article titled, A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies
Open the PDF for A Phase 1 Open-Label, Accelerated Dose-Escalation Study of the Hypoxia-Activated Prodrug AQ4N in Patients with Advanced Malignancies in another window
Journal Articles

The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development

Sanjay Goel, Marvin Cohen, S. Nilgün Çömezoglu, Lionel Perrin, François André, David Jayabalan, Lisa Iacono, Adriana Comprelli, Van T. Ly, Donglu Zhang, Carrie Xu, W. Griffith Humphreys, Hayley McDaid, Gary Goldberg, Susan B. Horwitz, Sridhar Mani
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (9): 2701–2709.
https://doi.org/10.1158/1078-0432.CCR-07-4151
Published: 01 May 2008
View article titled, The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development
Open the PDF for The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development in another window
Includes: Supplementary data
Journal Articles

A Safety Study of a Mixed-backbone Oligonucleotide (GEM231) Targeting the Type I Regulatory Subunit α of Protein Kinase A Using a Continuous Infusion Schedule in Patients with Refractory Solid Tumors

Sanjay Goel, Kavita Desai, Anca Bulgaru, Abbie Fields, Gary Goldberg, Sudhir Agrawal, Russell Martin, Michael Grindel, Sridhar Mani
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (11): 4069–4076.
Published: 30 September 2003
View article titled, A Safety Study of a Mixed-backbone Oligonucleotide (GEM231) Targeting the Type I Regulatory Subunit α of Protein Kinase A Using a Continuous Infusion Schedule in Patients with Refractory Solid Tumors
Open the PDF for A Safety Study of a Mixed-backbone Oligonucleotide (GEM231) Targeting the Type I Regulatory Subunit α of Protein Kinase A Using a Continuous Infusion Schedule in Patients with Refractory Solid Tumors in another window